Related Experiment Video
Updated: Aug 4, 2026

Trypsin Digest Protocol to Analyze the Retinal Vasculature of a Mouse Model
Published on: June 13, 2013
microRNA-26a-5p Prevents Retinal Neuronal Cell Death in Diabetic Mice by Targeting PTEN
Rui Shi1, Dan-Dan Liu1, Ying Cao1
1Department of Ophthalmology, Shaanxi Provincial People's Hospital, Xi'an, China.
Aim:
To explore the role of microRNA-26a-5p (miR-26a) in early diabetic retinal neuronal cell death and reveal the underlying mechanism(s).
Methods:
A streptozotocin (STZ)-induced diabetic mouse model was established using C57BL/6 J mice. Control or miR-26a mimic was intravitreally injected. Hematoxylin-eosin (H&E) and transmission electron microscopy (TEM) were used to observe the morphologic alterations in the retinal structure and ultrastructure, respectively. The expression of miR-26a and phosphatase and tensin homolog (PTEN) was assayed using qRT-PCR and western blotting, respectively. An immunofluorescence assay was used to investigate the distribution of PTEN expression in the retina. The expression of glial fibrillary acidic protein (GFAP) was measured to identify glial cell activation. The mRNA levels of IL-1β, NF-κB, and VEGF were examined to assess diabetic retinal inflammation.
Results:
miR-26a expression was decreased in retinal tissues of diabetic mice, and injection of miR-26a mimic restored the miR-26a level. Diabetic mice had significantly reduced neuroretinal thickness and ganglion cell number; miR-26a mimic delayed the thinning of neuroretinal layers and the loss of ganglion numbers. TEM showed damaged ultrastructure of retinal ganglions in diabetic mice, while miR-26a mitigated the damages. PTEN expression was increased mainly in the inner and outer nuclear layer of the retina in diabetic mice; miR-26a mimics lowered PTEN expression. GFAP, IL-1β, NF-κB, and VEGF expression were significantly increased in the diabetic mice, and intravitreal delivery of miR-26a resulted in a down-regulated expression of these factors.
Conclusion:
miR-26a can protect against retinal neuronal impairment in diabetic mice by down-regulating PTEN, highlighting the potential of miR-26a as a target for DR treatment.
Insights
MicroRNA-26a-5p (miR-26a) protects against diabetic retinal neuronal damage by reducing PTEN expression. This finding suggests miR-26a as a potential therapeutic target for diabetic retinopathy (DR).
Area of Science:
- Ophthalmology
- Molecular Biology
- Diabetology
Background:
- Diabetic retinopathy (DR) is a leading cause of vision loss, characterized by neuronal cell death.
- MicroRNAs (miRNAs) play crucial roles in regulating cellular processes, including neuronal survival.
- The specific role of microRNA-26a-5p (miR-26a) in diabetic retinal neurodegeneration remains to be fully elucidated.
Purpose of the Study:
- To investigate the role of miR-26a in early diabetic retinal neuronal cell death.
- To elucidate the underlying molecular mechanisms by which miR-26a influences diabetic retinal pathology.
Main Methods:
- Established a streptozotocin (STZ)-induced diabetic mouse model.
- Administered miR-26a mimic via intravitreal injection.
- Utilized Hematoxylin-eosin (H&E) staining, transmission electron microscopy (TEM), qRT-PCR, western blotting, and immunofluorescence assays to assess retinal structure, cell death, and molecular markers (PTEN, GFAP, IL-1β, NF-κB, VEGF).
Main Results:
- miR-26a levels were decreased in diabetic mouse retinas; miR-26a mimic injection restored these levels.
- miR-26a mimic treatment attenuated neuroretinal thinning, reduced ganglion cell loss, and mitigated ultrastructural damage in diabetic retinas.
- miR-26a mimic downregulated increased PTEN expression and reduced elevated levels of GFAP, IL-1β, NF-κB, and VEGF in diabetic retinas.
Conclusions:
- miR-26a protects retinal neurons from diabetic injury by down-regulating PTEN expression.
- Intravitreal delivery of miR-26a shows therapeutic potential for mitigating diabetic retinal neurodegeneration.
- miR-26a represents a promising therapeutic target for the treatment of diabetic retinopathy.
More Related Videos
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
04:36Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
Published on: January 12, 2024